Cantor Fitzgerald analyst Daniel Brims commented Tuesday that Valeant Pharmaceuticals Intl Inc. VRX may make dental acquisitions in 2015. Brims maintained a Buy rating on the company.
Possible targets based valuation, cost synergies and business overlap include Align Technology, Inc. ALGN, DENTSPLY International Inc. XRAY Henry Schein, Inc. HSIC and Patterson Companies, Inc. PDCO.
The above names were quiet in Tuesday’s trading session despite the analyst’s comments.
Valeant Pharmaceuticals Intl Inc. recently traded at $143.33, up 1.03 percent.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
